 PLANEGGMUNICH, GERMANY and WILMINGTON, DE ACCESSWIRE August 18, 2020 MorphoSys AG FSE:MOR; Prime Standard Segment; MDAX TecDAX; NASDAQ:MOR and Incyte Nasdaq:INCY today announced that Monjuvi tafasitamab-cxix, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines NCCN Guidelines in Oncology for B-cell Lymphomas. 